Dr. Johnson joined Sarah Cannon in 2014 and serves as the program director of lung cancer research. Her responsibilities include leading the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson continues to work in early phase Drug Development as well as lead the Solid Tumor Immune Effector Cellular Therapy program at Sarah Cannon. She also currently serves as the Chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tennessee. Dr. Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill where she was a Morehead scholar, and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute. She is board certified in internal medicine and medical oncology. Additionally, she is a partner of Tennessee Oncology, PLLC.

Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being on one of the co-discoverers of EGFR mutations, and findings from his work has led to the development of several clinical trials. In addition, he led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015.

I am an Associate Professor of Medicine at Indiana University School of Medicine and a thoracic oncologist at Indiana University Melvin and Bren Simon Cancer Center.

Puneeth Iyengar is a faculty in the Dept of Radiation Oncology at UT Southwestern Medical Center. He is also Associate Vice Chairman and Director of Clinical Research for the Dept of Radiation Oncology and Co-Leader of Thoracic Oncology at UTSW. His areas of clinical and research focus include local therapies for oligometastatic disease and radiation IO combinations for NSCLC and SCLC.

Wade Iams is an Assistant Professor of Medicine in thoracic medical oncology at Vanderbilt University Medical Center. His research interests include circulating biomarkers in patients with lung cancer and KRAS mutant non-small cell lung cancer.

Dr. Husain has developed a translational research focus to bring discoveries from bench-to-bedside. His efforts include expanding tools for tracking cancer growth specifically through circulating tumor DNA analyses and investigating how the genome can provide clues to optimal treatments and new therapies. Specifically, Dr. Husain's work has involved understanding mechanisms of resistance to targeted therapies, including anti-epidermal growth factor receptor (EGFR) treatments, and further characterizing the mechanisms of immunogenic cell death in cancer cells.

In my role, I lead the company

Kristin Higgins, M.D., specializes in the treatment of lung cancer. She completed residency in Radiation Oncology at Duke University, as well as an internship in internal medicine. She attended medical school at Tulane University in New Orleans, LA. She earned a B.S. in neuroscience at Vanderbilt University and graduated magna cum laude. Throughout her training Dr. Higgins received numerous honors, including induction into Alpha Omega Alpha Honor Medical Society, and the Roentgen Resident/Fellow Research Award at Duke University, and the ASCO Bradley Stuart Beller Merit Award. Dr. Higgins is an Associate Professor within the Emory School of Medicine and serves as the Medical Director of Radiation Oncology at the main campus location. She leads numerous Winship Clinical Trials that examine innovative treatment approaches in the treatment of lung cancer. One such clinical trial is LU005, A NRG Oncology/Alliance study comparing chemoradiation with or without immunotherapy for limited stage small cell lung cancer. This clinical trial is funded by the National Cancer Institute and provides a novel treatment approach for patients with newly diagnosed small cell lung cancer. Dr. Higgins has authored and coauthored over 60 scientific, peer-reviewed manuscripts and abstracts and given many oral presentations at national and international meetings. Dr. Higgins is a member of multiple professional organizations including the American Society for Radiation Oncology, the American Board of Radiology, the International Association for the study of Lung Cancer, The American Society of Clinical Oncology, and the Radiation Therapy Oncology Group.

John V. Heymach, MD, PhD is Chair of the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. As a physician-scientist, his research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for selecting patients most likely to benefit from targeted agents and immunotherapy. His research has led to new therapeutic approaches for KRAS mutant lung cancer, small cell lung cancer (SCLC), EGFR mutant non-small cell lung cancer, adenoid cystic carcinoma, and oligometastatic NSCLC, many of which are now considered standard of care regimens or undergoing clinical testing. He holds the David Bruton, Jr. Chair in Cancer Research. He attended Harvard College, where he graduated magna cum laude with a Chemistry B.A. degree and received his MD and PhD from Stanford. Dr. Heymach is a member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP) and is a Fellow of the American Association for the Advancement of Science (AAS). He has been awarded the Finneran Family Prize for translational cancer research and the Potu N. Rao Award for Excellence in Basic Science.

Roy S. Herbst, MD, PhD is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine. He is a fellow of the American Society of Clinical Oncology and the American College of Physicians, an elected member of the Association of American Physicians, and an elected member of the boards of directors for both AACR and the IASLC.

Dr. Herbst is a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments to patients, serving as principal investigator for trials leading to approval of several therapies revolutionizing the field and greatly enhancing patients’ lives.

He has more than 300 publications to his name, and his work published in Nature was awarded Clinical Research Forum’s 2015 Herbert Pardes Clinical Research Excellence Award. The NCI Lung SPORE Dr. Herbst leads has identified new mechanisms of sensitivity and resistance to immunotherapy. His work on "umbrella” trials, such as Lung MAP, has galvanized the field by developing public-private partnerships to conduct large clinical studies. He is a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes).